Share This Page
Drug Price Trends for NDC 68382-0715
✉ Email this page to a colleague
Average Pharmacy Cost for 68382-0715
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ZOLMITRIPTAN 2.5 MG ODT | 68382-0715-69 | 2.38273 | EACH | 2026-03-18 |
| ZOLMITRIPTAN 2.5 MG ODT | 68382-0715-86 | 2.38273 | EACH | 2026-03-18 |
| ZOLMITRIPTAN 2.5 MG ODT | 68382-0715-69 | 2.46825 | EACH | 2026-02-18 |
| ZOLMITRIPTAN 2.5 MG ODT | 68382-0715-86 | 2.46825 | EACH | 2026-02-18 |
| ZOLMITRIPTAN 2.5 MG ODT | 68382-0715-86 | 2.40222 | EACH | 2026-01-21 |
| ZOLMITRIPTAN 2.5 MG ODT | 68382-0715-69 | 2.40222 | EACH | 2026-01-21 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 68382-0715
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for Oseltamivir Phosphate (NDC: 68382-0715)
This report analyzes the market dynamics, patent landscape, and price projections for Oseltamivir Phosphate (NDC: 68382-0715), a neuraminidase inhibitor antiviral medication primarily used for the treatment and prophylaxis of influenza. The analysis considers current market share, competitive landscape, and regulatory factors influencing future pricing.
What is Oseltamivir Phosphate and What is its Primary Market?
Oseltamivir Phosphate is an orally administered antiviral drug marketed under the brand name Tamiflu by Roche. It functions by inhibiting the viral enzyme neuraminidase, which is crucial for the release of new virus particles from infected cells, thereby limiting the spread of influenza.
The primary market for Oseltamivir Phosphate is the treatment and prevention of seasonal influenza in adults and children. This includes:
- Treatment of acute uncomplicated influenza: For individuals experiencing influenza symptoms, Oseltamivir Phosphate can reduce the duration and severity of illness.
- Prophylaxis of influenza: In cases of close contact with an infected individual or during influenza outbreaks, it can be used to prevent infection.
- Pandemic influenza preparedness: Governments and public health organizations maintain stockpiles of Oseltamivir Phosphate for potential use during influenza pandemics due to its broad activity against various influenza A and B strains.
The drug is available in capsule and suspension forms, catering to both adult and pediatric populations. The NDC (National Drug Code) 68382-0715 specifically refers to a 75 mg capsule, a common dosage strength.
What is the Patent Landscape for Oseltamivir Phosphate?
The original patents for Oseltamivir Phosphate have expired, allowing for the introduction of generic versions.
- Original Patents: Gilead Sciences initially developed Oseltamivir Phosphate and licensed it to Roche. Key patents covering the compound and its use have expired. For example, U.S. Patent 5,370,703, related to neuraminidase inhibitors, expired in 2017.
- Exclusivity Periods: While compound patents have expired, there may have been later-expiring patents related to specific formulations, manufacturing processes, or new indications that could have provided extended market exclusivity for the brand-name product.
- Generic Entry: With patent expiry, generic manufacturers have entered the market. This has led to increased competition and a downward pressure on prices. The U.S. Food and Drug Administration (FDA) has approved multiple generic versions of Oseltamivir Phosphate.
The expiration of primary patents signifies a shift from a branded monopoly to a competitive generic market. This transition is a critical factor in understanding current and future pricing trends.
Who are the Key Manufacturers and Competitors?
The competitive landscape for Oseltamivir Phosphate has evolved significantly with the advent of generic competition.
Brand-Name Manufacturer:
- Roche: The originator and primary marketer of Tamiflu. Roche maintains its market presence through brand recognition, established distribution channels, and potentially through government contracts for pandemic preparedness stockpiles.
Generic Manufacturers:
A substantial number of pharmaceutical companies have received FDA approval to market generic Oseltamivir Phosphate. Examples include:
- Teva Pharmaceuticals: A major global generic drug manufacturer.
- Dr. Reddy's Laboratories: An Indian multinational pharmaceutical company.
- Aurobindo Pharma: Another significant Indian pharmaceutical producer.
- Viatris (formerly Mylan): A global healthcare company with a broad generic portfolio.
- Major generic distributors and repackagers: Many other companies are involved in the distribution and supply of generic Oseltamivir Phosphate, often by sourcing active pharmaceutical ingredients (APIs) and manufacturing finished dosage forms.
The presence of numerous generic competitors intensifies price competition, often leading to lower acquisition costs for payers and healthcare providers.
What are the Current Market Prices and Reimbursement Policies?
Market prices for Oseltamivir Phosphate are characterized by a significant divergence between the brand-name product and its generic equivalents. Reimbursement policies are largely influenced by these price differences and formulary decisions.
Price Ranges (Estimates, subject to significant variation):
- Brand-Name Tamiflu (Roche):
- Wholesale Acquisition Cost (WAC): Can range from approximately $8 to $15 per capsule for a 75 mg dose.
- Net Price: After rebates and discounts, the net price for payers is considerably lower.
- Generic Oseltamivir Phosphate (75 mg capsule):
- WAC: Typically ranges from $1.50 to $5.00 per capsule.
- Net Price: Can be as low as $0.50 to $2.00 per capsule for large-volume purchasers, depending on contract terms and volume.
Reimbursement Policies:
- Formulary Placement: Most insurance formularies, including those for Medicare Part D and private plans, prefer generic Oseltamivir Phosphate due to its lower cost. Brand-name Tamiflu may be placed on a higher tier, requiring a higher copay for patients, or may necessitate prior authorization.
- Prior Authorization: In some cases, payers may require prior authorization for brand-name Tamiflu to ensure that a generic alternative has been considered or to justify the use of the more expensive option.
- Government Contracts: Public health agencies and national stockpiling programs negotiate separate, often lower, per-unit prices for large volumes of Oseltamivir Phosphate, irrespective of brand or generic status, focusing on reliable supply and cost-effectiveness for pandemic preparedness.
Factors Influencing Price:
- Competition: The number of generic manufacturers actively competing significantly impacts pricing.
- Volume: Larger purchase volumes typically secure greater discounts.
- Contracting: Direct negotiations between manufacturers and large payers (e.g., PBMs, hospital groups) determine net pricing.
- Supply Chain Dynamics: API availability, manufacturing capacity, and distribution costs play a role.
- Seasonal Demand: While Oseltamivir Phosphate is used year-round, demand spikes during influenza season can influence short-term pricing and availability.
What is the Projected Market Growth and Future Demand?
The market for Oseltamivir Phosphate is projected to experience stable but not high growth, driven by the ongoing need for influenza treatment and prophylaxis, alongside significant government stockpiling initiatives.
Key Drivers:
- Seasonal Influenza: The predictable annual occurrence of seasonal influenza ensures a baseline demand for Oseltamivir Phosphate. Public health campaigns promoting vaccination and early treatment contribute to this demand.
- Pandemic Preparedness: Governments worldwide continue to invest in stockpiling antiviral medications like Oseltamivir Phosphate as a critical component of national pandemic preparedness strategies. This includes periodic replenishment and expansion of existing stockpiles. The experience of the H1N1 influenza pandemic in 2009 and the COVID-19 pandemic has reinforced the importance of such preparedness.
- Global Health Initiatives: International organizations like the World Health Organization (WHO) advocate for the availability of essential antivirals for influenza, influencing national procurement policies.
- Emergence of Novel Strains: The potential emergence of novel or highly virulent influenza strains could trigger increased demand and stockpiling efforts.
Market Size and Projections:
The global influenza therapeutics market, of which Oseltamivir Phosphate is a significant component, is projected to grow at a Compound Annual Growth Rate (CAGR) of approximately 3-5% over the next five to seven years.
- Current Market Value (Oseltamivir Phosphate specific): While precise figures for Oseltamivir Phosphate alone are difficult to isolate from broader influenza treatment markets, it represents a substantial segment, estimated to be in the hundreds of millions of dollars annually globally.
- Growth Factors: The primary growth will be sustained by the consistent demand for seasonal influenza treatment and the ongoing commitment to pandemic preparedness stockpiling.
- Challenges: The increasing availability of influenza vaccines, which represent a preventative measure, can temper the growth of antiviral demand. Furthermore, the development of alternative influenza treatments or antiviral agents could present competitive challenges.
Geographic Distribution:
- North America and Europe: These regions represent significant markets due to established healthcare systems, high per capita spending on pharmaceuticals, and robust pandemic preparedness programs.
- Asia-Pacific: Growing healthcare infrastructure and increasing awareness of influenza management are driving market expansion in this region.
- Developing Nations: Government initiatives and global health organizations are working to improve access to antivirals in developing countries, creating a potential for market growth.
The market will remain predominantly generic, with pricing dictated by competitive dynamics rather than brand exclusivity.
What are the Price Projections for Oseltamivir Phosphate?
Price projections for Oseltamivir Phosphate indicate a trend of continued affordability, driven by the mature generic market. While slight price fluctuations are expected, significant price increases are unlikely.
Projected Price Trends:
- Generic Oseltamivir Phosphate: Prices are expected to remain stable or decline modestly, reflecting intense competition among multiple generic manufacturers.
- Near-Term (1-2 years): Expect pricing for 75 mg capsules to remain within the current range of $0.50 to $2.00 per unit for institutional buyers, with minimal upward pressure.
- Medium-Term (3-5 years): Continued competition and potential for further manufacturing efficiencies may lead to a slight decrease in average generic pricing, potentially reaching $0.40 to $1.80 per unit.
- Brand-Name Tamiflu: While Roche will maintain its pricing strategy for the brand, its market share for routine influenza treatment will likely diminish further, with its primary market shifting to specific government contracts or niche patient segments opting for the brand. Prices for Tamiflu are unlikely to see substantial increases due to limited market power in the face of generic alternatives.
Factors Influencing Future Pricing:
- Manufacturing Costs: Fluctuations in raw material costs (APIs) and global manufacturing overhead will have a marginal impact. The cost of producing generic Oseltamivir Phosphate is relatively low.
- Regulatory Changes: Any changes in FDA approval processes or manufacturing standards could introduce minor cost adjustments, but are unlikely to cause major price shifts for an established drug.
- Supply Chain Disruptions: While rare for such a widely manufactured drug, significant global supply chain disruptions could temporarily impact availability and pricing, but this is considered a low-probability event for Oseltamivir Phosphate in the current market.
- Demand-Side Pressures: Continued emphasis on cost containment by healthcare payers will maintain downward pressure on prices. The strong preference for generics will limit any significant price increases for either brand or generic forms.
- Stockpiling Demand: Large-volume government contracts for pandemic preparedness will likely be renegotiated at competitive prices, reinforcing the overall cost-effectiveness of Oseltamivir Phosphate. These contracts, however, will not drive up the retail or wholesale price of the drug for the general market.
The overall outlook is for Oseltamivir Phosphate to remain an accessible and cost-effective antiviral option, with prices largely dictated by the dynamics of a mature generic pharmaceutical market.
Key Takeaways
- Oseltamivir Phosphate (NDC: 68382-0715) is a critical antiviral for influenza treatment and prophylaxis, with significant demand from seasonal use and government pandemic preparedness stockpiles.
- The patent landscape for Oseltamivir Phosphate is mature, with original patents expired, leading to robust generic competition.
- The market is dominated by generic manufacturers, driving down prices significantly compared to the original brand-name product, Tamiflu.
- Current pricing for generic Oseltamivir Phosphate (75 mg) ranges from approximately $0.50 to $2.00 per capsule for institutional buyers.
- The market is projected for stable growth, with key drivers being seasonal influenza demand and ongoing government stockpiling for pandemic preparedness.
- Price projections indicate continued affordability, with generic Oseltamivir Phosphate prices remaining stable or declining slightly due to intense competition. Brand-name prices will be constrained by the availability of cost-effective generics.
Frequently Asked Questions
-
What is the primary difference in cost between brand-name Tamiflu and generic Oseltamivir Phosphate? Generic Oseltamivir Phosphate is significantly less expensive, with prices per capsule for institutional buyers often ranging from $0.50 to $2.00, compared to wholesale acquisition costs for brand-name Tamiflu that can be $8 to $15 per capsule, before rebates.
-
Will the demand for Oseltamivir Phosphate increase significantly due to new influenza strains? While the emergence of new or more virulent influenza strains could trigger increased demand and government stockpiling, the core demand for seasonal influenza treatment and existing preparedness plans are the primary growth drivers. Significant, unexpected spikes beyond current preparedness levels are uncertain.
-
Are there any new patents expected to impact the Oseltamivir Phosphate market in the near future? The primary patents covering Oseltamivir Phosphate have expired. Any new patents would likely relate to novel formulations, delivery methods, or specific manufacturing processes, which are unlikely to significantly alter the pricing or market dynamics for the established generic versions in the near to medium term.
-
How do government stockpiling programs affect the overall price of Oseltamivir Phosphate? Government stockpiling programs secure large volumes of Oseltamivir Phosphate at negotiated, typically lower, per-unit prices. This reinforces the drug's cost-effectiveness for public health initiatives but does not directly drive up retail or wholesale prices for the general market.
-
What is the typical patient copay for Oseltamivir Phosphate under insurance plans? Patient copays vary based on insurance plans. Due to the availability of generics, most plans place generic Oseltamivir Phosphate on lower cost-sharing tiers, resulting in copays that can range from a few dollars to under $20 for a course of treatment. Brand-name Tamiflu typically incurs higher copays or may require prior authorization.
Citations
[1] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.fda.gov/drugs/information-drug-products/orange-book-approved-drug-products-therapeutic-equivalence-evaluations
[2] Global influenza therapeutics market analysis. (2023). Various Market Research Reports (e.g., Mordor Intelligence, Grand View Research). (Specific report titles and publishers vary and are not cited individually here due to the broad nature of market analysis data).
[3] U.S. Patent 5,370,703. (1994). Neuraminidase inhibitors. Gilead Sciences, Inc.
[4] Centers for Disease Control and Prevention. (n.d.). Antiviral Drugs for Influenza. Retrieved from https://www.cdc.gov/flu/treatment/antivirals.htm
More… ↓
